Latest Headlines

Latest Headlines

Merck KGaA's cancer vaccine endures another clinical failure

Tecemotide, Merck KGaA's 9-lived cancer vaccine, has flunked another clinical trial, missing its main goal in a Japanese study and casting further doubts on the program's future.

Merck KGaA doubles down on Oncothyreon's failed cancer vaccine

Shares of Oncothyreon soared this morning after its partner Merck KGaA said it would take a second swipe at trying to find some value in Stimuvax, the cancer vaccine (now renamed tecemotide) that has already decisively flunked a Phase III trial.

Merck KGaA: Lung cancer vaccine not dead

Despite flunking a Phase III trial in December, Merck KGaA is still talking about its lung cancer vaccine. The company has decided to push on with another ongoing late-phase trial in Asia and is now weighing the options of starting a further study.

Oncothyreon routed after Merck KGaA's Stimuvax flops in PhIII lung cancer trial

After taking its big Phase III study of Stimuvax all the way to a conclusive finish, Merck KGaA said the closely-watched lung cancer vaccine failed to demonstrate a significant improvement in overall survival--a flop that will leave a deep scar at Oncothyreon as well, which licensed out the treatment.

Existing drugs boost new cancer vax responses

Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.

MUC1 cancer vaccine starts in the clinic

Oncothyreon ($ONTY), which takes its name from the Greek words for 'tumor' and 'shield', has enrolled the first patient into its inaugural ONT-10 clinical trial.

Oncothyreon shares routed as Stimuvax PhIII trial soldiers on

Merck KGaA told analysts today that after assessing its late-stage study for the lung cancer vaccine Stimuvax in a second interim analysis, investigators were told to push on to an ultimate read-out...

Cancer immunotherapy partners face big test with Phase III program

Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set

Oncothyreon awaits pivotal data on Stimuvax

Oncothyreon ($ONTY) execs are expecting interim results from a late-stage study of lung cancer vaccine Stimuvax sometime this quarter. Results from the 1,514-person trial, which is being conducted by...

Cancer immunotherapies in vogue as specialists seek a "cure"

Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of